CH stock · Healthcare sector · Biotechnology
Company Logo

CRISPR Therapeutics AG

CRSPNASDAQ

75.85

USD
-4.29
(-5.35%)
Market Closed
21.31P/E
-10Forward P/E
1.02P/E to S&P500
5.917BMarket CAP
- -Div Yield
Scale: |
View:
Currency: USD, in millions
2014
2015
2016
2017
2018
2019
2020
2021
Income Statement
Revenue
- -
0
5
41
3
290
1
915
COGS
- -
- -
- -
- -
- -
- -
- -
- -
Gross Profit
- -
- -
- -
- -
- -
- -
- -
915
Gross Profit Ratio
- -
- -
- -
- -
- -
- -
- -
100.00%
Operating Expenses
7
26
73
106
162
243
355
541
R&D Expenses
2
13
42
70
114
179
267
439
Selling, G&A Exp.
5
13
31
36
48
63
88
103
General and Admin. Exp.
5
13
31
36
48
63
88
103
Selling and Marketing Exp.
- -
- -
- -
- -
- -
- -
- -
- -
Other Expenses
- -
- -
- -
- -
- -
- -
- -
- -
COGS and Expenses
7
26
73
106
162
243
355
541
Interest Income
- -
- -
- -
- -
- -
- -
- -
- -
Interest Expense
- -
0
8
- -
- -
- -
- -
- -
Depreciation and Amortization
0
0
1
3
4
5
9
18
EBITDA
(7)
(26)
(14)
(64)
(161)
72
(339)
397
EBITDA ratio
(Infinity)%
(10,358.70)%
(266.13)%
(155.09)%
(5,150.74)%
24.87%
(47,131.02)%
43.44%
Operating Income
(7)
(26)
(68)
(65)
(159)
47
(354)
374
Operating Income ratio
(Infinity)%
(10,416.60)%
(1,319.33)%
(157.69)%
(5,087.80)%
16.14%
(49,295.55)%
40.82%
Total Other Income Exp.(Gains)
(0)
(0)
45
(2)
(5)
21
6
6
Income Before Tax
(7)
(26)
(23)
(67)
(164)
67
(348)
380
Income Before Tax ratio
(Infinity)%
(10,453.85)%
(439.93)%
(162.47)%
(5,263.38)%
23.24%
(48,408.34)%
41.48%
Income Tax Expense (Gain)
(0)
0
0
2
1
0
1
2
Net Income
(7)
(26)
(23)
(68)
(165)
67
(349)
378
Net Income Ratio
(Infinity)%
(10,456.68)%
(449.30)%
(166.74)%
(5,281.08)%
23.09%
(48,520.86)%
41.28%
EPS
(0.23)
(1.26)
(1.89)
(1.71)
(3.44)
1.23
(5.29)
4.97
EPS Diluted
(0.23)
(1.26)
(1.89)
(1.71)
(3.44)
1.17
(5.29)
4.70
Weighted Avg. Shares Outs.
29
20
12
40
48
54
66
66
Weighted Avg. Shares Outs. Dil.
29
20
12
40
48
57
66
66
Balance Sheet
Cash and Cash Equivalents
1
156
316
240
457
944
1,169
923
Short-Term Investments
- -
- -
- -
- -
- -
- -
522
1,456
Cash & Short-Term Investments
1
156
316
240
457
944
1,690
2,379
Net Receivables
- -
0
3
3
0
0
0
0
Inventory
- -
- -
- -
- -
- -
- -
- -
- -
Other Current Assets
0
1
2
6
10
44
26
38
Total Current Assets
1
157
320
248
466
988
1,717
2,418
PP&E
- -
1
21
19
19
73
93
312
Goodwill
- -
- -
- -
- -
- -
- -
- -
- -
Intangible Assets
1
0
0
0
0
- -
- -
0
Goodwill and Intangible Assets
1
0
0
0
0
0
0
0
Investments
- -
- -
- -
- -
- -
- -
- -
- -
Tax Assets
- -
- -
- -
- -
- -
- -
- -
- -
Other Non-Current Assets
0
1
3
4
4
6
18
22
Total Non-Current Assets
1
3
25
23
23
79
111
334
Other Assets
- -
- -
- -
- -
- -
- -
- -
- -
Total Assets
2
159
345
271
489
1,067
1,828
2,752
Accounts Payable
0
2
5
2
5
6
9
15
Short-Term Debt
- -
- -
- -
- -
- -
8
11
12
Tax Payable
0
0
0
0
0
1
10
1
Deferred Revenue
- -
- -
- -
- -
- -
1
2
1
Other Current Liabilities
2
9
17
13
23
42
71
92
Total Current Liabilities
2
10
22
15
28
57
94
120
Long-Term Debt
- -
38
- -
- -
- -
- -
50
213
Deferred Revenue
- -
75
78
57
58
12
12
12
Deferred Tax Liabilities
- -
- -
- -
- -
- -
- -
- -
- -
Other Non-Current Liabilities
6
65
12
12
11
58
8
7
Total Non-Current Liabilities
6
178
90
69
69
70
69
233
Other Liabilities
- -
- -
- -
- -
- -
- -
- -
- -
Capital Lease Obligations
- -
- -
- -
- -
- -
53
61
225
Total Liabilities
9
189
112
84
97
127
164
352
Preferred Stock
- -
- -
- -
- -
- -
- -
- -
- -
Common Stock
0
0
1
1
2
2
2
2
Retained Earnings
(8)
(34)
(57)
(125)
(292)
(225)
(574)
(196)
Other Compreh. Income(Loss)
(0)
(0)
(0)
0
(0)
0
(0)
(5)
Other Total Stockhold. Equity
1
5
289
312
682
1,162
2,236
2,600
Total Stockholders Equity
(7)
(29)
233
188
392
939
1,664
2,399
Total Liab.&Stockhold. Equity
1
159
345
271
489
1,067
1,828
2,752
Minority Interest
0
(0)
- -
- -
- -
- -
- -
- -
Total Liabilities & Equity
2
159
345
271
489
1,067
1,828
2,752
Cash Flow Statement
Net Income
(7)
(26)
(23)
(68)
(165)
67
(349)
378
Depreciation and Amortization
0
0
1
3
4
5
9
18
Deferred Income Tax
- -
- -
- -
- -
- -
- -
- -
- -
Stock Based Compensation
1
4
11
19
35
44
66
102
Change in Working Capital
2
81
2
(25)
11
(48)
33
27
Accounts Receivable
- -
(0)
(3)
1
3
(0)
(0)
(0)
Inventory
- -
- -
- -
- -
- -
- -
- -
- -
Accounts Payable
- -
- -
- -
- -
- -
- -
- -
- -
Other Working Capital
(0)
75
2
(21)
(1)
(46)
1
9
Other Non-Cash Items
(0)
0
(46)
2
20
(11)
2
14
Cash Provided by Operating Activities
(5)
59
(55)
(70)
(96)
57
(238)
539
CAPEX
- -
(1)
(3)
(8)
(3)
(7)
(18)
(82)
Acquisitions Net
- -
- -
(0)
- -
- -
- -
- -
- -
Purchases of Investments
- -
- -
- -
(1)
- -
- -
(594)
(1,509)
Sales/Maturities of Investments
- -
- -
- -
- -
- -
- -
71
556
Other Investing Activities
- -
- -
35
- -
- -
8
- -
- -
Cash Used for Investing Activities
- -
(1)
32
(8)
(3)
1
(541)
(1,035)
Debt Repayment
- -
- -
- -
- -
- -
- -
- -
- -
Common Stock Issued
0
- -
89
- -
307
415
982
213
Common Stock Repurchased
- -
- -
- -
- -
(0)
- -
- -
- -
Dividends Paid
- -
- -
- -
- -
- -
- -
- -
- -
Other Financing Activities
5
97
94
3
9
16
34
38
Cash Used/Provided by Financing Activities
5
97
183
3
316
431
1,016
251
Effect of Forex Changes on Cash
0
0
(0)
0
(0)
0
0
(0)
Net Change In Cash
1
155
160
(76)
217
489
237
(246)
Cash at the End of Period
1
156
316
240
460
949
1,185
940
Cash at the Beginning of Period
0
1
156
316
243
460
949
1,185
Free Cash Flow
(5)
58
(58)
(78)
(99)
50
(257)
457
Forex Rate
- -
- -
- -
- -
- -
- -
- -
- -